STOCK TITAN

Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

HERTFORDSHIRE, England and PITTSBURGH, July 22, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs., Aug. 6, before the open of the U.S. financial markets. The company also will host a webcast at 10:30 a.m. ET on Aug. 6 to discuss the results.

The briefing can be accessed live by calling 855.493.3607 or 346.354.0950 for international callers (ID#: 4267916) or at the following address on the company's website: investor.mylan.com.  A replay of the webcast also will be available on the website. 

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

"Mylan

 

"Cision" View original content to download multimedia:http://www.prnewswire.com/news-releases/mylan-to-release-second-quarter-2020-financial-results-on-aug-6-2020-301097679.html

SOURCE Mylan N.V.

MYL

NASDAQ:MYL

MYL Rankings

MYL Latest News

MYL Stock Data

0
Pharmaceuticals: Generic
Health Technology
Link
GB
Hatfield

About MYL

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.